Business
WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT
WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Represents early progress against targeted milestones anticipated for 2023 to expand\n \n \n company growth\n \n \n \n \n \n CALGARY\n \n , AB and MOUNTAIN VIEW, Calif\n \n ,\n \n \n Jan. 17, 2023\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today a follow-on engagement with Sandhill One, LLC (\n \n www.sandhillone.com\n \n ) (\"Sandhill\") for the next phase in optimizing a proprietary enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (\"API\") used in nutraceutical and pharmaceutical products. This represents the continuation of the project, the first phase of which the Company announced\n \n May 31, 2022\n \n .\n \n \n \n \n \n \n \n \n \n Sandhill is partnered with a large-cap, multi-national healthcare company and the targeted product is manufacture of the large volume API, ursodeoxycholic acid (UDCA). UDCA is used as a medication for the management and treatment of cholestatic liver disease and gallstone conditions, and as an important intermediate for production of tauroursodeoxycholic acid (TUDCA), a key API in a combination therapy recently approved in\n \n Canada\n \n and\n \n the United States\n \n for treatment of amyotrophic lateral sclerosis (ALS). The process under development between the Company and Sandhill represents a step-change in the production of UDCA, as it will not rely on animal-sourced raw materials, as is the case with most current manufacturing of UDCA and other cholic acids, and is expected to be lower in cost.\n \n \n In this next phase of development, the Company anticipates several hundred thousand U.S. dollars in research fees, along with a milestone payme...